All In Biotech

NDA 211882 · Bausch

Arazlo

Tazarotene · Topical · Retinoid

Last checked: Nov 19, 2026Latest source record: Dec 18, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Dec 18, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

61

15 Phase 3, 0 recruiting

FAERS reports

350

137 serious, 3 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 26, 2023.

ARAZLO ® (tazarotene) lotion, 0.045% is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. ARAZLO is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. ( 1 )

Mechanism: Tazarotene is a retinoid prodrug which is converted to its active form, tazarotenic acid, the carboxylic acid of tazarotene, by deesterification. Tazarotenic acid binds to all three members of the retinoic acid receptor (RAR) family: RARα, RARβ and RARγ, but shows relative selectivity for RARβ, and RARγ and may modify gene expression. The clinical significance of these findings for the treatment of acne vulgaris is unknown.

Therapeutic areas: Ophthalmology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ARAZLO · TAZAROTENE 0.045% · LOTION, TOPICAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Tazarotene" as an intervention, any sponsor and status, largest first.

All 61 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective55
  • off label use34
  • headache21
  • diarrhoea17
  • nausea16
  • product use in unapproved indication16
  • dry skin15
  • psoriasis15
  • application site discolouration14
  • pain14
  • skin exfoliation14
  • treatment failure14

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042
20061
20073
20083
20092
20103
20114
20122
20131
20142
20154
201613
20173
201811
201922
202013
202120
202240
202372
202448
202535
202646

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Arazlo (Tazarotene)

2024 spending

$352K

Beneficiaries

390

625 claims

Per beneficiary

$903

$11.42 per unit

View as table
YearSpending
2020$19,711
2021$112,085
2022$217,070
2023$289,846
2024$352,261

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 171 on PubMed

Sponsor: Bausch

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.